Zhou et al. conducted an analysis of the effects of the IL-23/IL-23R pathway in IL-23 receptor-positive esophageal squamous cell carcinoma (ESCC IL-23R+). This evidence concerns the gene IL37 and esophageal squamous cell carcinoma.